In a study in which 390,000 people received a single dose of Johnson & Johnson’s COVID-19 vaccine, the drugmaker found that the single dose provided 79 percent protection against infection and 81 percent protection against hospitalization.
When participants received a booster dose 56 days after their first dose, the study found that they had 100 percent protection against severe COVID-19 at least 14 days after their second dose. It also found that the recipients had 94 percent protection against symptomatic COVID-19 in the U.S. and 75 percent protection against symptomatic COVID-19 globally.
Johnson & Johnson also found that when participants received a booster dose six months after initial vaccination, antibody levels increased ninefold one week after the booster and rose to a twelvefold increase four weeks after the booster. The drugmaker said all antibody increases “were irrespective of age.”
“A single-shot COVID-19 vaccine that is easy to use, distribute and administer, and that provides strong and long-lasting protection is crucial to vaccinating the global population,” Paul Stoffels, MD, Johnson & Johnson’s chief scientific officer, said in a statement. “At the same time, we now have generated evidence that a booster shot further increases protection against COVID-19 and is expected to extend the duration of protection significantly.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
